Clinical Trials Overview

Clinical Trials Overview

Tvardi is conducting Phase 2 clinical trials with TTI-101, an oral drug that inhibits STAT3, a protein that plays a key role in cancer and fibrosis.

In cancer, STAT3 can lead to tumor growth and metastasis, as well as limit the body’s ability to mount an immune response against cancer cells.

In fibrotic conditions, such as Idiopathic Pulmonary Fibrosis (IPF), STAT3 plays a key role in fibrosis (scarring of lung tissues) and limits the body’s ability to repair damaged cells.

Human studies have shown that TTI-101 has the potential to benefit patients with conditions where STAT3 plays a central role, including cancer and IPF.  TTI-101 is a pill taken by mouth twice daily.

Phase 2: REVERT Liver Cancer Clinical Trial

TTI-101 as Monotherapy and in Combination for Hepatocellular Carcinoma
(Currently Recruiting)

Phase 2: REVERT IPF Clinical Trial

TTI-101 in Idiopathic Pulmonary Fibrosis
(Currently Recruiting)

Phase 1: TTI-101 in Patients with Advanced Cancers

TTI-101 in Advanced Cancers
(Completed Recruiting)

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.